[Use of the aldosterone antagonist, canrenoate potassium for treating chronic circulatory insufficiency].
The results of studying the clinical effect of the diuretic soldacton and its effect on a number of indices of water-electrolyte metabolism are discussed. The drug was used in 16 patients with IIB--III stage of circulatory insufficiency. It was found that soldacton possesses a moderate diuretic and natriuretic effect and produces a potassium-preserving effect. The drug is effective in various initial concentrations of plasma aldosterone which does not change significantly under its effect. Soldacton promotes improvement of tolerance to cardiac glycosides and diminishes the risk of the development of digitalis intoxication.
D000328:Adult; D000368:Aged; D000450:Aldosterone / Q000097:blood; D002191:Canrenoic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy; D004077:Digoxin / Q000008:administration & dosage; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000451:Mineralocorticoid Receptor Antagonists; D011245:Pregnadienes / Q000627:therapeutic use*; D011660:Pulmonary Heart Disease / Q000188:drug therapy; D012214:Rheumatic Heart Disease / Q000188:drug therapy; D014882:Water-Electrolyte Balance / Q000187:drug effects
D000451:Mineralocorticoid Receptor Antagonists; D011245:Pregnadienes; D000450:Aldosterone; D004077:Digoxin; D002191:Canrenoic Acid
Primenenie antagonista al'dosterona kanrenoata kaliia dlia lecheniia bol'nykh s khronicheskoĭ nedostatochnost'iu krovoobrashcheniia.